There was a study published in the journal Nature that described a promising new combination therapy for the treatment of men with advanced prostate cancers that are non-responsive to chemotherapy. The study is entitled “Immunosuppressive Plasma Cells Impede T-Cell Dependent Immunogenic Chemotherapy.” The study was conducted at the University of California, San Diego.
Prostate cancers are also non-responsive to an encouraging new type of drugs based on immunotherapy called checkpoint inhibitors, which are drugs often able to trigger a stronger immune response to better fight cancer.
It has been suggested that resistance to treatment of advanced prostate cancer is in part due to the body developing an accumulation of cells that suppress the immune system. These cell types are called immunosuppressive immune B cells. They can negatively control the immune system and interfere w